The DOI matches its Crossref record.
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
Abstract
To the Editor: We recently reported (April 18 issue)1 the sustained correction of X-linked severe combined immunodeficiency disease by ex vivo, retrovirally mediated transfer of the γc gene into CD34+ cells in four of five patients with the disease. These results have since been confirmed in four additional patients with typical X-linked severe combined immunodeficiency. Of the first four successfully treated patients, three continue to do well up to 3.6 years after gene therapy, whereas a serious adverse event occurred in the fourth patient. At a routine checkup 30 months after gene therapy, lymphocytosis consisting of a monoclonal population . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lentiviral vectors are considered safer than gamma-retroviral vectors in terms of their semi-random integration patterns, as gene integration does not preferentially occur in start regions of active genes (93-95).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [93]
Citations
Cites
No references could be resolved yet.
Cited by
Sorted by citations
Items 201–300 of 1,003
Clinical application of genetically modified T cells in cancer therapy
Kershaw, M. H., Westwood, J. A., Slaney, C. Y., & Darcy, P. K. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.7 · Cited by 109
Stem cell based therapies to treat muscular dystrophy
Price, F. D., Kuroda, K., & Rudnicki, M. A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.08.011 · Cited by 119
“However, the process of genetic alteration has in the past led to undesirable effects including transformation of donor cells and even death [44–46].”
BackgroundFuture of local bone regeneration - Protein versus gene therapy.
Fischer, J., Kolk, A., Wolfart, S., Pautke, C., Warnke, P., Plank, C., & Smeets, R. (2011) · Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery · doi:10.1016/j.jcms.2010.03.016 · Cited by 117
“, 2000), several patients developed a leukaemia-like condition caused by “insertional mutagenesis” (Hacein-Bey-Abina et al., 2003).”
BackgroundUnique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy.
Shou, Y., Ma, Z.-J., Lu, T., & Sorrentino, B. (2006) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0603635103 · Cited by 116
Exploiting T Cells Specific for Human Minor Histocompatibility Antigens For Therapy of Leukemia
Bleakley, M., & Riddell, S. R. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2010.124 · Cited by 115
Non-viral gene delivery carrier and its three-dimensional transfection system
He, C., Tabata, Y., & Gao, J.-Q. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.11.006 · Cited by 107
Raftery, R. M., Castaño, I. M., Chen, G., Cavanagh, B., Quinn, B., Curtin, C. M., Cryan, S., & O’Brien, F. J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.036 · Cited by 135
“A major concern in using gene therapy is integration of the gene into the cellular genome, inducing over-expression of encoded proteins for a prolonged time, usually permanently [53].”
BackgroundMesenchymal stem cells at the intersection of cell and gene therapy
Myers, T. J., Granero‐Moltó, F., Longobardi, L., Li, T., Yan, Y., & Spagnoli, A. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.531257 · Cited by 105
“In clinical studies using bone marrow cells to deliver IL-2 to X-linked severe combined immunodeficiency patients in Europe, despite promising results, some patients developed leukemia-like symptoms leading to death, probably due to the insertion of the IL-2 gene near an oncogene [4].”
Momin, E. N., Vela, G., Zaidi, H. A., & Quiñones‐Hinojosa, A. (2010) · Current Immunology Reviews · doi:10.2174/157339510791111718 · Cited by 106
“Four of the 10 patients in the trial developed a T-cell acute lymphoblastic leukemia-like disease [144–148].”
BackgroundGenome-wide mapping of foamy virus vector integrations into a human cell line.
Nowrouzi, A., Dittrich, M., Klanke, C., Heinkelein, M., Rammling, M., Dandekar, T., von Kalle, C., & Rethwilm, A. (2006) · Journal of General Virology · doi:10.1099/vir.0.81554-0 · Cited by 113
“…effects that occurred after gene correction of X-linked severe combined immunodeficiency by gammaretroviral murine leukemia virus (MLV)-derived vectors has stimulated research into alternative retroviral vector systems that show a more inert integration profile (Hacein-Bey-Abina et al., 2003).”
BackgroundInfluentialDesigning nonviral vectors for efficient gene transfer and long-term gene expression.
Jackson, D., Juranek, S., & Lipps, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.026 · Cited by 112
Systemic mRNA delivery to the lungs by functional polyester-based carriers
Yan, Y., Xiong, H., Zhang, X., Cheng, Q., & Siegwart, D. J. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b01356 · Cited by 111
Baruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 111
Gene therapy for cancer: regulatory considerations for approval
Husain, S., Han, J., Au, P., Shannon, K., & Puri, R. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.58 · Cited by 111
Hama, S., Akita, H., Iida, S., Mizuguchi, H., & Harashima, H. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1165 · Cited by 111
“However, many clinical trials in which viral vectors are used have been interrupted since the application of these vectors induced unexpected adverse effects such as immunogenicity (3) and oncogenicity (4).”
BackgroundDNA bar coding and pyrosequencing to analyze adverse events in therapeutic gene transfer
Wang, G. P., Garrigue, A., Ciuffi, A., Ronen, K., Leipzig, J. N., Berry, C. C., Lagresle‐Peyrou, C., Benjelloun, F., Hacein‐Bey‐Abina, S., Fischer, A., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn125 · Cited by 104
“Lentiviral (PGK) vector in artemis-deficient mice 401 Healthy control LN 1647 (65) 117 (4) 7.”
BackgroundSelf-citationShort interfering RNA (siRNA): tool or therapeutic?
Cejka, D., Losert, D., & Wacheck, V. (2005) · Clinical Science · doi:10.1042/cs20050162 · Cited by 106
Methods for Gene Transfer to the Central Nervous System
Kantor, B., Bailey, R. M., Wimberly, K., Kalburgi, S. N., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00003-2 · Cited by 109
Berges, B. K., & Rowan, M. R. (2011) · Retrovirology · doi:10.1186/1742-4690-8-65 · Cited by 111
“These vectors are capable of genomic integration and long-term gene delivery, and do not appear to be accompanied by the leukemic events that can occur with oncoretroviruses [111].”
BackgroundGene therapy for severe combined immunodeficiencies
Gaspar, H. B., & Thrasher, A. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.9.1175 · Cited by 109
“However, in one SCID-X1 gene therapy study, 3 of 11 patients who had shown successful immune recovery following gene therapy developed T cell leukaemia 3 years after treatment ([42,43] and Cavazzana-Calvo et al.”
BackgroundTen years of gene therapy for primary immune deficiencies
Aiuti, A., & Roncarolo, M. G. (2009) · Hematology · doi:10.1182/asheducation-2009.1.682 · Cited by 105
“This leukemia-like disease was the result of vector-mediated up-regulation of host cellular oncogenes by the MLV LTR.25,28,29 Gammaretroviral vectors naturally insert into active genes, and the strong enhancer elements found in the viral LTR can transactivate neighboring promoters leading to aberrant gene expression.”
BackgroundRETRACTED: Gene therapy and wound healing
Eming, S. A., Krieg, T. M., & Davidson, J. M. (2007) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2006.09.011 · Cited by 100
“Nonetheless, recent reports highlight the risk of vector-induced target cell transformation in human gene therapy trials (51,52).”
BackgroundRetractedPatient monitoring and follow‐up in lentiviral clinical trials
McGarrity, G. J., Hoyah, G., Winemiller, A., Andre, K., Stein, D., Blick, G., Greenberg, R. N., Kinder, C., Zolopa, A., Binder‐Scholl, G., et al. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2691 · Cited by 109
“to the insertion of the vector in or near regulatory sequences of the LMO2 proto-oncogene [6,7].”
BackgroundRapid endosomal escape of prickly nanodiamonds: implications for gene delivery
Chu, Z., Miu, K. K., Lung, P.-S., Zhang, S., Zhao, S., Chang, H.-C., Lin, G., & Li, Q. (2015) · Scientific Reports · doi:10.1038/srep11661 · Cited by 108
Quenneville, S. P., Chapdelaine, P., Skuk, D., Paradis, M., Goulet, M., Rousseau, J., Xiao, X., Garcia, L., & Tremblay, J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300047 · Cited by 108
Immune Responses to Lentiviral Vectors
Follenzi, A., Santambrogio, L., & Annoni, A. (2007) · Current Gene Therapy · doi:10.2174/156652307782151515 · Cited by 87
Gene Therapy Approaches for Bone Regeneration
Franceschi, R. T., Yang, S., Rutherford, R. B., Krebsbach, P. H., Zhao, M., & Wang, D. (2004) · Cells Tissues Organs · doi:10.1159/000075031 · Cited by 106
“Hacein-Bey-Abina, S., C. von Kalle, M. Schmidt, F. Le Deist, N. Wulffraat, E. McIntyre, I. Radford, J.L. Villeval, C.C. Fraser, M. CavazzanaCalvo, A. Fischer (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.”
Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9
LaFountaine, J. S., Fathe, K., & Smyth, H. D. C. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.08.029 · Cited by 111
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges
Lipowska‐Bhalla, G., Gilham, D. E., Hawkins, R. E., & Rothwell, D. G. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1254-0 · Cited by 109
Fifteen Years of Gene Therapy Based on Chimeric Antigen Receptors: “Are We Nearly There Yet?”
Dotti, G., Savoldo, B., & Brenner, M. K. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.142 · Cited by 93
“This observation markedly contrasts with experience in patients receiving hematopoietic stem cells (HSCs) that have been similarly modified with gammaretroviruses (Hacein-Bey-Abina et al. , 2003, 2008).”
Site-specific recombination in human embryonic stem cells induced by cell-permeant Cre recombinase
Nolden, L., Edenhofer, F., Haupt, S., Koch, P., Wunderlich, F., Siemen, H., & Brüstle, O. (2006) · Nature Methods · doi:10.1038/nmeth884 · Cited by 105
“resulting in the malignant transformation of cells as has been shown in a recent clinical tria”
BackgroundNonintegrating Gene Therapy Vectors
Athanasopoulos, T., Munye, M. M., & Yáñez‐Muñoz, R. J. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.007 · Cited by 134
Raftery, R. M., Walsh, D. P., Castaño, I. M., Heise, A., Duffy, G. P., Cryan, S., & O’Brien, F. J. (2016) · Advanced Materials · doi:10.1002/adma.201505088 · Cited by 123
Meacham, J. M., Durvasula, K., Degertekin, F. L., & Fedorov, A. G. (2013) · SLAS TECHNOLOGY · doi:10.1177/2211068213494388 · Cited by 122
Genetically modified mesenchymal stromal cells in cancer therapy
Sage, E. K., Thakrar, R. M., & Janes, S. M. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.09.003 · Cited by 118
“[66] Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F,”
BackgroundCationic liposome/DNA complexes: from structure to interactions with cellular membranes
Caracciolo, G., & Amenitsch, H. W. (2012) · European Biophysics Journal · doi:10.1007/s00249-012-0830-8 · Cited by 109
Efficient Lentiviral Transduction and Improved Engraftment of Human Bone Marrow Mesenchymal Cells
Damme, A. V., Thorrez, L., Ma, L., Vandenburgh, H. H., Eyckmans, J., Dell’Accio, F., Bari, C. D., Luyten, F. P., Lillicrap, D., Collen, D., et al. (2005) · Stem Cells · doi:10.1634/stemcells.2003-0106 · Cited by 101
Dillon, C. P., Sandy, P., Nencioni, A., Kissler, S., Rubinson, D. A., & Parijs, L. V. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.67.040403.130716 · Cited by 95
Extended Survival of Glioblastoma Patients After Chemoprotective HSC Gene Therapy
Adair, J. E., Beard, B. C., Trobridge, G. D., Neff, T., Rockhill, J. K., Silbergeld, D. L., Mrugala, M. M., & Kiem, H. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003425 · Cited by 104
“In previous clinical trials using gene-modified cells with an intrinsic growth advantage (X-SCID), a reduced clonal repertoire was observed that eventually led to frank leukemia (28).”
Biasco, L., Ambrosi, A., Pellin, D., Bartholomae, C. C., Brigida, I., Roncarolo, M. G., Serio, C. D., Kalle, C. V., Schmidt, M., & Aiuti, A. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000108 · Cited by 104
“…occurred in the SCIDX1 GT clinical trials, a number of studies have focused their attention on the influences of the vector on neighbouring genes (Hacein-Bey-Abina et al, 2003b, 2008; Howe et al, 2008; Maruggi et al, 2009; Ott et al, 2006) as well as how these could lead to clonal dominance and…”
BackgroundSelf-citationRahim, A. A., Wong, A. M. S., Howe, S. J., Buckley, S. M. K., Acosta-Saltos, A. D., Elston, K. E., Ward, N. J., Philpott, N. J., Cooper, J. D., Anderson, P. N., et al. (2009) · Gene Therapy · doi:10.1038/gt.2008.186 · Cited by 101
Peng, P., Cohen, C. J., Yang, S.-C., Hsu, C., Jones, S., Zhao, Y., Zheng, Z.-L., Rosenberg, S. A., & Morgan, R. A. (2009) · Gene Therapy · doi:10.1038/gt.2009.54 · Cited by 100
Fleury, S., Simeoni, E., Zuppinger, C., Déglon, N., von Segesser, L., Kappenberger, L., & Vassalli, G. (2003) · Circulation · doi:10.1161/01.cir.0000065598.46411.ef · Cited by 100
Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy
Hackett, P. B., Largaespada, D. A., Switzer, K. C., & Cooper, L. J. N. (2013) · Translational research · doi:10.1016/j.trsl.2012.12.005 · Cited by 97
Morgan, R. A., Dudley, M. E., & Rosenberg, S. A. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181eb3879 · Cited by 93
Arthritis gene therapy's first death
Evans, C. H., Ghivizzani, S. C., & Robbins, P. D. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2411 · Cited by 87
“2002 X-linked severe combined Retrovirus Leukemia developed, linked to insertion Yes [5] immunodeficiency of retrovirus adjacent to the LMO2 oncogene promoter”
BackgroundInfluentialNew Insights and Unresolved Issues Regarding Insertional Mutagenesis in X-linked SCID Gene Therapy
Pike‐Overzet, K., van der Burg, M., Wagemaker, G., van Dongen, J. J. M., & Staal, F. J. T. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300297 · Cited by 101
Argyros, O., Wong, S. P., Niceta, M., Waddington, S. N., Howe, S. J., Coutelle, C., Miller, A. D., & Harbottle, R. P. (2008) · Gene Therapy · doi:10.1038/gt.2008.113 · Cited by 96
Long-Term Type VII Collagen Restoration to Human Epidermolysis Bullosa Skin Tissue
Siprashvili, Z., Nguyen, N., Bezchinsky, M. Y., Marinkovich, M., Lane, A. T., & Khavari, P. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.023 · Cited by 96
“The insertional activation of the LMO2 proto-oncogene and subsequent induction of leukemia in patients undergoing a hematopoietic stem cell human gene therapy trial (Hacein-Bey-Abina et al. , 2003a,b) precipitated a careful investigation of the use of retroviruses in human trials.”
Lufino, M. M., Edser, P. A. H., & Wade‐Martins, R. (2008) · Molecular Therapy · doi:10.1038/mt.2008.156 · Cited by 97
Custom zinc-finger nucleases for use in human cells.
Alwin, S., Gere, M. B., Guhl, E., Effertz, K., Barbas, C., Segal, D., Weitzman, M., & Cathomen, T. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.374 · Cited by 96
Genetic Modification of T Lymphocytes for Adoptive Immunotherapy
Rössig, C., & Brenner, M. K. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.04.014 · Cited by 86
Cell-Based Vascularization Strategies for Skin Tissue Engineering
Hendrickx, B., Vranckx, J. J., & Luttun, A. (2010) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2010.0315 · Cited by 94
Akita, H., Kogure, K., Moriguchi, R., Nakamura, Y., Higashi, T., Nakamura, T., Serada, S., Fujimoto, M., Naka, T., Futaki, S., et al. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.023 · Cited by 94
Niwano, K., Arai, M., Koitabashi, N., Watanabe, A., Ikeda, Y., Miyoshi, H., & Kurabayashi, M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.61 · Cited by 94
Albert, M., Liu, Y., Anasetti, C., & Yu, X.-Z. (2005) · European Journal of Immunology · doi:10.1002/eji.200526077 · Cited by 94
Protein based therapeutic delivery agents: Contemporary developments and challenges
Yin, L., Yuvienco, C., & Montclare, J. K. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.04.036 · Cited by 112
Impact of Bee Venom Enzymes on Diseases and Immune Responses
Hossen, M. S., Shapla, U. M., Gan, S., & Khalil, M. (2016) · Molecules · doi:10.3390/molecules22010025 · Cited by 93
“However, these methods are not free of several adverse issues, such as the development of autoimmunity and cross-reactivity, competition between epitopes from the vector and the antigen for presentation, and safety and regulatory problems [56,57].”
Mashel, T. V., Tarakanchikova, Y. V., Muslimov, A. R., Zyuzin, M. V., Timin, A. S., Lepik, K. V., & Fehse, B. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120282 · Cited by 102
Chromosomal Integration of Adenoviral Vector DNA In Vivo
Stephen, S. L., Montini, E., Sivanandam, V. G., Al-Dhalimy, M., Kestler, H. A., Finegold, M. J., Grompe, M., & Kochanek, S. (2010) · Journal of Virology · doi:10.1128/jvi.00751-10 · Cited by 91
“with a retroviral vector (9, 10), the consideration of genotoxic”
BackgroundLü, X., Yu, Q., Binder, G. K., Chen, Z., Slepushkina, T., Rossi, J. J., & Dropulić, B. (2004) · Journal of Virology · doi:10.1128/jvi.78.13.7079-7088.2004 · Cited by 88
“Lentivirus-based vectors may be safer than the commonly used Moloney murine leukemia virus (MoMuLV)-based retroviral vector, since MoMuLV has been shown to cause leukemia in mice (14, 43) and recently in two children transplanted with stem cells modified with the virus (2, 15, 16).”
MethodInsertional oncogenesis in gene therapy: how much of a risk?
Sadelain, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302243 · Cited by 92
Functional correction of type VII collagen expression in dystrophic epidermolysis bullosa.
Murauer, E., Gache, Y., Gratz, I., Klausegger, A., Muss, W., Gruber, C., Meneguzzi, G., Hintner, H., & Bauer, J. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.249 · Cited by 92
Layek, B., & Singh, J. P. (2013) · Biomacromolecules · doi:10.1021/bm301720g · Cited by 91
Shen, Z., Brayman, A. A., Chen, L., & Miao, C. H. (2008) · Gene Therapy · doi:10.1038/gt.2008.51 · Cited by 84
Meyer, S. D. D., Vanhoorelbeke, K., Chuah, M., Pareyn, I., Gillijns, V., Hebbel, R., Collen, D., Deckmyn, H., & VandenDriessche, T. (2006) · Blood · doi:10.1182/blood-2005-09-3605 · Cited by 91
Ultrasound Enhances Gene Delivery of Human Factor IX Plasmid
Miao, C. H., Brayman, A., Loeb, K., Ye, P., Zhou, L., Mourad, P. D., & Crum, L. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.893 · Cited by 91
Kiem, H., Sellers, S., Thomasson, B. M., Morris, J., Tisdale, J., Horn, P., Hematti, P., Adler, R. L., Kuramoto, K., Calmels, B., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.006 · Cited by 91
Self-citationCurrent concepts in meniscus surgery: resection to replacement
Sgaglione, N. A., Steadman, J. R., Shaffer, B., Miller, M. D., & Fu, F. H. (2003) · Arthroscopy The Journal of Arthroscopic and Related Surgery · doi:10.1016/j.arthro.2003.10.032 · Cited by 87
Immunization delivered by lentiviral vectors for cancer and infectious diseases
Hu, B., Tai, A., & Wang, P. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00967.x · Cited by 88
“c-Retroviral vectors (c-RVs), another vector system that has been studied, carry the risk of severe insertional mutagenesis in patients (16); however, LVs have been shown to provide a lower risk of genotoxicity from transgene integration and are therefore favored (10).”
BackgroundTan, W., Zhu, K., Segal, D., Barbas, C., & Chow, S. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.3.1301-1313.2004 · Cited by 90
“Development of leukemia associated with the use of retroviral vectors in gene therapy trials has been reported (22, 36), but the level of risk of cancer and other side effects caused by insertional mutagen-”
BackgroundLong-term safety of lentiviral or gammaretroviral gene-modified T cell therapies
Jadlowsky, J. K., Hexner, E. O., Marshall, A., Grupp, S. A., Frey, N. V., Riley, J. L., Veloso, E. A., McConville, H., Rogal, W., Czuczman, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03478-6 · Cited by 91
Novel strategies exploiting interleukin-12 in cancer immunotherapy
Cirella, A., Luri‐Rey, C., Trani, C. A. D., Teijeira, Á., Olivera, I., Bolaños, E., Álvarez, E. C., Palencia, B., Brocco, D., Fernández-Sendin, M., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108189 · Cited by 104
Tan, W., Dong, Z., Wilkinson, T. A., Barbas, C., & Chow, S. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.4.1939-1948.2006 · Cited by 89
“The importance of insertional mutagenesis is further highlighted by reports of leukemia in mice and infants after the administration of retrovirus-based vectors (24, 38).”
BackgroundQuenneville, S. P., Chapdelaine, P., Rousseau, J., Beaulieu, J., Caron, N., Skuk, D., Mills, P., Olivares, E. C., Calos, M. P., & Tremblay, J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.05.034 · Cited by 89
“For example, retroviral vectors randomly insert their expression cassettes and could lead to tumor development [26].”
BackgroundSheehy, E. J., Kelly, D. J., & O’Brien, F. J. (2019) · Materials Today Bio · doi:10.1016/j.mtbio.2019.100009 · Cited by 99
Beard, B. C., Keyser, K. A., Trobridge, G. D., Peterson, L. J., Miller, D. G., Jacobs, M., Kaul, R., & Kiem, H. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.011 · Cited by 81
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy
Hamilton, M. P., Sugio, T., Noordenbos, T., Shi, S., Bulterys, P. L., Liu, C. L., Kang, X., Olsen, M. N., Good, Z., Dahiya, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401361 · Cited by 223
Measles and rubella elimination in the WHO Region for Europe: progress and challenges
O’Connor, P. M., Jankovic, D., Muscat, M., Mamou, M. C. B., Reef, S. E., Papania, M. J., Singh, S., Kaloumenos, T., Butler, R., & Datta, S. S. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.01.003 · Cited by 123
Custom-designed zinc finger nucleases: What is next?
Wu, J. S., Kandavelou, K., & Chandrasegaran, S. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7206-8 · Cited by 87
Genetic, cellular and immune approaches to disease therapy: past and future
Nabel, G. J. (2004) · Nature Medicine · doi:10.1038/nm990 · Cited by 87
“And unfortunately, the feature of SCID-X1 deficiency that led to success conferred an unexpected side effect: the uncontrolled proliferation of the gene-modified T cells in several subjects 41 , possibly related to insertional activation of an oncogene in these cells 42 .”
BackgroundKenderian, S. S., Porter, D. L., & Gill, S. I. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.002 · Cited by 86
Kurtzberg, J., Lyerly, A., & Sugarman, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26690 · Cited by 85
“Unfortunately, the initial experience utilizing gene therapy for the treatment of X-linked SCID (resulting from γ chain gene mutations), although successful in obtaining gene transfection, expression, and clinical correction of the immune defect, resulted in the unanticipated, aberrant insertion of the vector near an…”
BackgroundProspects and implications of using chromatin insulators in gene therapy and transgenesis.
Recillas-Targa, F., Valadez-Graham, V., & Farrell, C. (2004) · Bioessays · doi:10.1002/bies.20059 · Cited by 85
Nichols, T. C., Dillow, A. M., Franck, H. W. G., Merricks, E. P., Raymer, R. A., Bellinger, D. A., Arruda, V. R., & High, K. A. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.144 · Cited by 73
“In addition, sustained expression with nonintegrating vectors is an important achievement that addresses safety concerns about integrating vectors (Donsante et al. 2007; Hacein-Bey-Abina et al. 2003).”
BackgroundDupré, L., Marangoni, F., Scaramuzza, S., Trifari, S., Hernández, R. J., Aiuti, A., Naldini, L., & Roncarolo, M. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.303 · Cited by 84
Efficient Colorectal Cancer Gene Therapy with IL-15 mRNA Nanoformulation
Lei, S., Zhang, X., Men, K., Gao, Y., Yang, X., Wu, S., Duan, X., Wei, Y., & Tong, R. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00451 · Cited by 83
Advanced Materials and Nanotechnology for Drug Delivery
Yan, L., Yang, Y., Zhang, W.-J., & Chen, X. (2014) · Advances in Materials · doi:10.1002/adma.201305683 · Cited by 83
Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer
Pike‐Overzet, K., Rodijk, M., Ng, Y.-Y., Baert, M. R. M., Lagresle‐Peyrou, C., Schambach, A., Zhang, F., Hoeben, R. C., Hacein‐Bey‐Abina, S., Lankester, A. C., et al. (2011) · Leukemia · doi:10.1038/leu.2011.106 · Cited by 90
Self-citationClinical development on the frontier: gene therapy for duchenne muscular dystrophy
Asher, D. R., Thapa, K., Dharia, S. D., Khan, N., Potter, R. A., Rodino‐Klapac, L. R., & Mendell, J. R. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1725469 · Cited by 91
AAV9 Vector: a Novel modality in gene therapy for spinal muscular atrophy
Pattali, R. K., Mou, Y., & Li, X.-J. (2019) · Gene Therapy · doi:10.1038/s41434-019-0085-4 · Cited by 100
Majzoub, R. N., Chan, C.-L., Ewert, K., Silva, B. F. B., Liang, K., Jacovetty, E. L., Carragher, B., Potter, C., & Safinya, C. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.007 · Cited by 82
Shirazi, R. S., Ewert, K., Leal, C., Majzoub, R. N., Bouxsein, N. F., & Safinya, C. (2011) · Biochimica et Biophysica Acta · doi:10.1016/j.bbamem.2011.04.020 · Cited by 82
Chonco, L., Bermejo-Martín, J., Ortega, P., Shcharbin, D. G., Pedziwiatr, E., Klajnert, B., de la Mata, F. J., Eritja, R., Gómez, R., Bryszewska, M., et al. (2007) · Organic and biomolecular chemistry · doi:10.1039/b703989a · Cited by 82
Cell Penetrating Peptide Conjugated Chitosan for Enhanced Delivery of Nucleic Acid
Layek, B., Lipp, L., & Singh, J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226142 · Cited by 91
“Although most of the ongoing or approved gene therapy protocols use viral vectors for gene delivery, there is increasing interest in developing nonviral vectors to circumvent viral associated safety issues such as potential infectivity, immunogenicity, inflammation, and insertional mutagenesis [19–22].”
BackgroundHematopoietic stem cell engineering at a crossroads
Rivière, I., Dunbar, C. E., & Sadelain, M. (2011) · Blood · doi:10.1182/blood-2011-09-349993 · Cited by 80
van Lunzen, J., Glaunsinger, T., Stahmer, I., von Baehr, V., Baum, C., Schilz, A., Kuehlcke, K., Naundorf, S., Martinius, H., Hermann, F., et al. (2007) · Molecular Therapy · doi:10.1038/mt.sj.6300124 · Cited by 81
Gene therapy clinical trials worldwide to 2023—an update
Ginn, S. L., Mandwie, M., Alexander, I. E., Edelstein, M. L., & Abedi, M. R. (2024) · The Journal of Gene Medicine · doi:10.1002/jgm.3721 · Cited by 100
Zhang, T., Huang, B. Y., Wu, H., Wu, J., Li, L., Li, Y.-X., Hu, Y., Han, M. Y., Shen, Y., Tabata, Y., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.007 · Cited by 85
Gene Transfer: How Can the Biological Barriers Be Overcome?
Escoffre, J., Teissié, J., & Rols, M. (2010) · Journal of Membrane Biology · doi:10.1007/s00232-010-9275-0 · Cited by 79
“Moreover, retrovirus- or lentivirus-derived vectors could evoke insertional mutations during their integration into the host genome (Hacein-Bey-Abina et al. 2003a, b).”
Background
Metadata
- Authors
- Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., & Fischer, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-01-16
- Volume
- 348
- Issue
- 3
- Pages
- 255-256
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2323613689
- Cited by
- 1,867
- References
- 0
- Citations by year
- 2026: 29 · 2025: 32 · 2024: 31 · 2023: 25 · 2022: 47 · 2021: 52 · 2020: 46 · 2019: 50 · 2018: 45 · 2017: 63 · 2016: 65 · 2015: 84 · 2014: 87 · 2013: 92 · 2012: 92
- FWCI
- 86.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- X-linked severe combined immunodeficiency, gene therapy, adverse events, gene therapy safety
- MeSH terms
- Chromosomes, Human, Pair 11, DNA-Binding Proteins, Humans, Genetic Linkage, Metalloproteins, Proto-Oncogene Proteins, Retroviridae, Genetic Therapy, Gene Expression, Mutagenesis, Insertional, Severe Combined Immunodeficiency, Lymphocyte Count, Chromosomes, Human, X, Adaptor Proteins, Signal Transducing, Precursor Cell Lymphoblastic Leukemia-Lymphoma, LIM Domain Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
